Agenus (NASDAQ:AGEN) Cut to Hold at Baird R W

Baird R W cut shares of Agenus (NASDAQ:AGEN) from a strong-buy rating to a hold rating in a research note issued to investors on Friday morning, Zacks.com reports.

Other research analysts also recently issued reports about the company. HC Wainwright downgraded Agenus from a buy rating to a neutral rating and dropped their price objective for the company from $40.00 to $9.00 in a research note on Thursday. Robert W. Baird downgraded Agenus from an outperform rating to a neutral rating and dropped their price target for the stock from $35.00 to $8.00 in a research note on Friday. Jefferies Financial Group reaffirmed a hold rating and set a $7.00 price target (up from $3.00) on shares of Agenus in a research note on Friday. William Blair downgraded Agenus from an outperform rating to a market perform rating in a research note on Thursday. Finally, StockNews.com started coverage on Agenus in a research note on Wednesday, April 17th. They set a hold rating on the stock. Six research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of Hold and an average price target of $31.00.

Agenus Price Performance

Shares of NASDAQ:AGEN opened at $5.99 on Friday. The company has a market capitalization of $125.79 million, a price-to-earnings ratio of -0.47 and a beta of 1.32. The business’s 50-day moving average is $14.33 and its 200-day moving average is $12.82. Agenus has a 1 year low of $4.78 and a 1 year high of $34.20.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($3.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.58) by $0.54. The business had revenue of $28.01 million during the quarter, compared to analyst estimates of $40.70 million. Analysts anticipate that Agenus will post -9.7 EPS for the current year.

Hedge Funds Weigh In On Agenus

Several institutional investors have recently modified their holdings of AGEN. Vanguard Group Inc. grew its holdings in shares of Agenus by 1.6% in the third quarter. Vanguard Group Inc. now owns 26,938,439 shares of the biotechnology company’s stock valued at $30,440,000 after acquiring an additional 432,202 shares in the last quarter. Exchange Traded Concepts LLC grew its holdings in shares of Agenus by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 107,019 shares of the biotechnology company’s stock valued at $89,000 after acquiring an additional 27,137 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Agenus by 526.6% in the fourth quarter. SG Americas Securities LLC now owns 198,735 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 167,017 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Agenus by 3,008.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,306,248 shares of the biotechnology company’s stock valued at $1,909,000 after acquiring an additional 2,232,064 shares in the last quarter. Finally, Values First Advisors Inc. grew its holdings in shares of Agenus by 7.8% in the fourth quarter. Values First Advisors Inc. now owns 269,829 shares of the biotechnology company’s stock valued at $223,000 after acquiring an additional 19,568 shares in the last quarter. 61.46% of the stock is owned by institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.